News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
5 Biotechs That Have Major Catalysts Coming in the Next 6 to 9 Months 3/22/2017
Onxeo To Present Data Supporting Three Key Orphan Oncology Assets At AACR Annual Meeting 3/22/2017
For Sale: Nektar Therapeutics (NKTR) Plans to License Hot New Opioid Drug 3/21/2017
Investors Squeal With Delight as Eli Lilly (LLY)'s Breast Cancer Combo Succeeds in Phase III, Faces Tough Competition from Pfizer (PFE) and Novartis AG (NVS) 3/21/2017
Neurocrine Biosciences (NBIX) Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia 3/21/2017
RedHill Biopharma (RDHL) Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn’s Disease 3/21/2017
Array BioPharma (ARRY) Withdraws Skin Cancer NDA for Binimetinib 3/20/2017
Boehringer Ingelheim Phase III Study Now Enrolling Patients With Progressive Fibrosing Lung Diseases 3/20/2017
Janssen Pharmaceutical Release: New Phase III Study Finds XARELTO To Be Superior To Aspirin For Long-Term Prevention Of Recurrent Blood Clots Without Observing Any Significant Increase In Major Bleeding In Patients With Venous Thromboembolism 3/20/2017
Eli Lilly (LLY) Announces Phase III MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint Of Progression-Free Survival 3/20/2017
Jazz Pharma (JAZZ) Announces Positive Results From The Phase III TONES 3 And TONES 4 Studies Of JZP-110 In Patients With Obstructive Sleep Apnea 3/20/2017
BeyondSpring Pharmaceuticals Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted For Poster Presentation At The 2017 Keystone Symposia In British Columbia 3/20/2017
Palatin Tech (PTN) Receives Notice Of Allowance On Bremelanotide Methods Of Use Patent For Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women 3/20/2017
Humacyte Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Expedited Review Designation For HUMACYL In Vascular Access For Hemodialysis 3/20/2017
Resverlogix (RVX.TO) Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase III Study Of Apabetalone And Provides An Update On Corporate Activities 3/17/2017
Eli Lilly (LLY) Release: First Dedicated Outcome Trials Of Empagliflozin In Chronic Heart Failure Initiated 3/17/2017
Agile Therapeutics, Inc. Announces A Poster Presentation Of Its SECURE Phase III Study At The Contraceptive Technology 2017 Conference 3/17/2017
Bristol-Myers Squibb (BMY) And Pfizer (PFE) Present Large Real-World Observational Analysis Of The Effectiveness And Safety Of Direct Oral Anticoagulants Compared To Warfarin In Patients With Non-Valvular Atrial Fibrillation 3/17/2017
AstraZeneca PLC (AZN) Steals Tesaro (TSRO)'s PARP Thunder With Phase III Ovarian Cancer Data 3/16/2017
Alkermes (ALKS) Initiates Phase III Gastrointestinal Tolerability Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 3/16/2017
Jazz Pharma (JAZZ) Announces First Patient Enrolled In Phase III Clinical Study Evaluating JZP-258 For The Treatment Of Cataplexy And Excessive Daytime Sleepiness In Narcolepsy 3/16/2017
PHARNEXT Announces Initiation Of Phase III Extension Study PLEO-CMT-FU Of PXT3003 For Treatment Of Charcot-Marie-Tooth Disease Type 1A 3/16/2017
New Publication Describes Positive Patient Experience In Study Of Ocular Therapeutix (OCUL)’s DEXTENZA Following Cataract Surgery 3/15/2017
Vtesse Completes Enrollment Of Phase IIb/III Pivotal Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 3/15/2017
FDA Demands Karyopharm (KPTI) Stop Enrollment of All Selinexor Trials 3/14/2017
LSK BioPharma Announces Enrollment Of First Patient In Phase III Apatinib Trial In Gastric Cancer 3/14/2017
AbbVie (ABBV) Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C 3/14/2017
One Death in the HAVEN 1 Trial Complicates Roche (RHHBY)’s Entry into the Hemophilia A Market 3/13/2017
Investors Anxiously Await for Amgen (AMGN)'s 27,500-Patient Heart Trial Data This Week 3/13/2017
Amgen (AMGN) Release: Repatha (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase III Study 3/13/2017
Pfizer (PFE) And Merck & Co. (MRK) Go For An Even Longer Throw Of The Javelin 3/10/2017
DBV Tech Announces Completion Of Enrollment Of The REALISE Study In Peanut Allergic Children 3/10/2017
TiGenix Announces Positive Topline Week-104 Data For Cx601 ADMIRE-CD Trial 3/9/2017
Ipsen (IPN.PA) Announces Data Presentations Of Lanreotide (Somatuline Autogel), Telotristat Ethyl And The Investigational Compound 177Lu-OPS201 At The European Neuroendocrine Tumor Society (ENETS) 2017 Conference 3/9/2017
Aurinia (AUPH) Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Operational Highlights 3/9/2017
Allergan (AGN) Release: FDA Accepts Supplemental New Drug Application (sNDA) For VRAYLAR (cariprazine) 3/8/2017
Achieve Life Science And OncoGenex (OGXI) Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT") 3/8/2017
DalCor's Phase III Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule 3/7/2017
Akcea Therapeutics And Ionis Pharma (IONS) Announce Positive Results From Pivotal Study Of Volanesorsen In Patients With Familial Chylomicronemia Syndrome (FCS) 3/7/2017
Shire (SHPG) Release: CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy 3/7/2017
TiGenix Receives Positive Feedback From The FDA On Cx601 Global Phase III Trial Protocol 3/7/2017
ObsEva (OBSV) Starts Phase III Clinical Program For Nolasiban In ART 3/7/2017
Not Giving Up: Roche (RHHBY) To Start New Phase III Tests With Once-Failed Alzheimer's Drug 3/7/2017
Revance (RVNC) Completes Enrollment In Phase III Pivotal Trials Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines 3/7/2017
TG Therapeutics (TGTX) Rockets After Leukemia Drug Clears Hurdle in Late-Stage Study 3/6/2017
Chinese Billionaire's Biotech Hutchison China MediTech (Chi-Med) Shows Off Phase III Cancer Drug Data 3/6/2017
ImmunoCellular Therapeutics (IMUC) Provides Update On ICT-107 Phase III Glioblastoma Trial And Announces Advances In Stem-To-T-Cell Research Program 3/6/2017
Regeneron (REGN) And Sanofi (SNY) Announce Presentation Of Positive Data From Long-Term Pivotal Phase III CHRONOS Study Of DUPIXENT (Dupilumab) In Moderate-To-Severe Atopic Dermatitis 3/6/2017
Daiichi Sankyo Initiates ENTRUST-AF PCI Study Investigating Once-Daily SAVAYSA (Edoxaban) In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention With Stenting 3/6/2017
Bristol-Myers Squibb (BMY) And Pfizer (PFE) To Present New Analyses Of Eliquis (Apixaban) Clinical And Real-World Data At American College of Cardiology 2017 Scientific Session 3/6/2017
ARCA biopharma Announces 175th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial 3/6/2017
Exelixis (EXEL)' Cabozantinib Granted Orphan Drug Designation For The Treatment Of Hepatocellular Carcinoma 3/6/2017
Amgen (AMGN) Presents New Data From Phase III XGEVA (Denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop 3/6/2017
CEL-SCI (CVM) Gives Update On Partial Clinical Hold On Phase 3 Head And Neck Cancer Study With Multikine 3/6/2017
Akcea Therapeutics And Ionis Pharma (IONS) Announce Positive Results From Pivotal Study Of Volanesorsen In Patients With Familial Chylomicronemia Syndrome (FCS) 3/6/2017
GlaxoSmithKline (GSK)'s MUSCA Study Shows Nucala (Mepolizumab) Significantly Improves Quality Of Life And Lung Function In Severe Asthma Patients With An Eosinophilic Phenotype 3/6/2017
Advanced Accelerator Applications Announces Presentation Of Quality Of Life Findings From NETTER-1 Phase III Study At ENETS 3/6/2017
Dermira (DERM) And UCB Group (UCBJF.PK) Release: New CIMZIA (Certolizumab Pegol) Data In Moderate-To-Severe Plaque Psoriasis And Psoriatic Arthritis Presented At American Academy of Dermatology 2017 Annual Meeting 3/6/2017
Aimmune (AIMT) Presents Clinical Data On Phase III Screening And Phase 2 Adherence For AR101 For Peanut Allergy At The 2017 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting 3/6/2017
Amgen (AMGN) Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase III ENDEAVOR Trial At 16th International Myeloma Workshop 3/6/2017
Genentech (RHHBY) New Breast Cancer Cocktail Cuts Deaths in Phase III Study, Roche (RHHBY) Stock Soars 3/3/2017
10 Biotechs With an Orphan Drug in Late-Stage Pipeline 3/3/2017
Novartis AG (NVS) Puts Cancer Hopes on 4 Star Scientists Poached From Harvard Last Year 3/3/2017
Janssen R&D Release: New Results From Second Phase III Study Show Significant Efficacy Of Guselkumab And Superiority Versus Humira In Treatment Of Moderate To Severe Plaque Psoriasis 3/3/2017
AEterna Zentaris (AEZS) Announces Presentation Regarding Macrilen At 99th Annual Meeting Of The Endocrine Society 3/3/2017
Lexicon Pharma (LXRX) Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results 3/3/2017
Dermira (DERM) Presents New Data In Primary Axillary Hyperhidrosis And Acne At American Academy of Dermatology 2017 Annual Meeting 3/3/2017
Kamada Ltd. (KMDA) To Host R&D Day Focused On Graft Versus Host Disease (GvHD) 3/3/2017
MorphoSys AG Announces That Its Licensee Janssen R&D Has Reported New Data From Two Phase III Studies Of Guselkumab In Plaque Psoriasis 3/3/2017
Kite Pharma (KITE)'s CAR-T Blood Cancer Candidate Succeeds in Major Study 3/2/2017
PTC Therapeutics (PTCT) Announces Results From Pivotal Phase III Clinical Trial Of Ataluren In Patients Living With Nonsense Mutation Cystic Fibrosis 3/2/2017
Myovant (MYOV) Initiates Phase III Clinical Trial Of Relugolix In Men With Advanced Prostate Cancer 3/2/2017
Bristol-Myers Squibb (BMY) To Present Data That Advances Understanding Of Effects Of Immuno-Oncology Therapies On Cancer Biology And Patient Outcomes At AACR 2017 3/2/2017
bluebird bio (BLUE) Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal of Medicine 3/2/2017
NovoCure Announces Data Presentations At The AACR Annual Meeting 2017 3/2/2017
Stealth Biotherapeutics Initiates Observational Study Of Patients With Mitochondrial Myopathy 3/2/2017
Achaogen (AKAO) Highlights Emerging Pipeline Of Antibacterials Including A New Orally-Administered Antibiotic Clinical Candidate At Company's R&D Day 3/2/2017
PTC Therapeutics (PTCT) Ditches Cystic Fibrosis Drug After Trial Failure 3/2/2017
Despite 13 Reported Deaths in 2016, Aurinia (AUPH)'s Lupus Nephritis Drug Shows No New Safety Concerns 3/2/2017
ImmunoGen (IMGN) Announces Presentations At AACR Annual Meeting 3/2/2017
Merck & Co. (MRK), Eli Lilly (LLY) Failure Puts Alzheimer's Drug Development Spotlight on Rival Genentech (RHHBY) 3/1/2017
Ligand (LGND) Provides Highlights From Today’s Analyst Day Event 3/1/2017
LSK BioPharma's Apatinib Receives Orphan Drug Designation In The European Union 3/1/2017
CSL Behring Release: Largest Ever CIDP Clinical Study Completed 3/1/2017
Frustration Sets In as Accera's Alzheimer's Drug Flunks Late-Stage Trial 2/28/2017
Amgen (AMGN) Release: Phase III Head-To-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 2/28/2017
ASIT Biotech Reports Positive Results In Its Phase III Clinical Trial With Gp-ASIT+ For Grass Pollen Induced Allergic Rhinitis 2/28/2017
Gamida Cell Announces First Patient Transplanted In Phase III Registration Study Of Nicord For Blood Cancers 2/28/2017
Johns Hopkins Medicine, Maryland Stem Cell Research Fund And BioCardia Announce First Patient Treated With CardiAMP Cell Therapy For Ischemic Heart Failure In Phase III Clinical Trial 2/28/2017
Adamas Pharma (ADMS) Presents Additional Open-Label, Long-Term Safety And Efficacy Data On ADS-5102 At The First Pan American Parkinson’s Disease And Movement Disorders Congress 2/28/2017
Atlantic Healthcare Confirms Alicaforsen Targets TLR-9, Providing A Second Mechanism Of Action To Treat New And Existing Inflammatory Indications 2/28/2017
Roche (RHHBY) Reports Death in Phase III Hemophilia Study 2/27/2017
La Jolla Pharma (LJPC)'s Low Blood Pressure Med Meets Phase III Study Goals 2/27/2017
In First Phase III Trial, Merck & Co. (MRK)’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced The Incidence Of Confirmed Herpes Zoster Cases By An Estimated 64 Percent In Immunocompromised Subjects 2/27/2017
Merck & Co. (MRK)’s Letermovir, An Investigational Antiviral Medicine For Prevention Of Cytomegalovirus (CMV) Infection In Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant In Pivotal Phase III Study 2/27/2017
XBiotech (XBIT) Reports Affirmative Interim Analysis Of Global Phase III Colorectal Cancer Study 2/27/2017
AcelRx (ACRX)' New Drug Application For DSUVIA Accepted For Filing With PDUFA Date Of October 12, 2017 2/27/2017
AbbVie (ABBV) Receives CHMP Positive Opinion For Eight-Week Treatment Option With VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C 2/27/2017
Sunovion Announces Positive Topline Results From Study Evaluating Latuda (Lurasidone HCL) In Children And Adolescents With Bipolar Depression 2/27/2017
RegeneRx Biopharmaceuticals, Inc. (RGRX) Licensee Receives FDA Permission To Conduct A Phase III Trial Of RGN-137 For Epidermolysis Bullosa In U.S. 2/27/2017
AMAG (AMAG) And Palatin Tech (PTN) Announce Rekynda Data Presentations At The International Society For The Study Of Women’s Sexual Health Annual Meeting 2/27/2017
Recro Pharma (REPH) Completes Enrollment In Phase III Safety Study Of IV Meloxicam 2/27/2017
ALK-Abello A/S's ACARIZAX Data Results In Significant Change To The GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended As A Treatment Option In Patients With House Dust Mite Allergic Asthma 2/27/2017
Shire (SHPG) Release: CHMP Recommends EU Conditional Marketing Authorisation For Natpar (Parathyroid Hormone) For Patients With Chronic Hypoparathyroidism 2/27/2017
ASIT Biotech Will Publish The Results Of The Phase III Clinical Trial With Its Gp-ASIT+ Product Candidate For Treating Grass Pollen Rhinitis On 28 February, 2017 2/27/2017
NoNO, Inc Initiates Phase III Study Of NA-1 For Acute Ischemic Stroke 2/27/2017
Why 2017 Will be a Data-Rich and Not Revenue-Focused Year for bluebird bio (BLUE) 2/24/2017
Investors Breathe a Sigh of Relief Cempra (CEMP)'s Skin Infection Drug Hits Phase III Goals 2/24/2017
Auris Med (EARS) Receives FDA Fast Track Designation For AM-111 In Acute Sensorineural Hearing Loss 2/24/2017
Augmenix Release: Phase 3 Trial Data Show Use Of SpaceOAR Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment 2/24/2017
Novartis AG (NVS)'s Cancer Drug Gets a Fast Track Ticket From the FDA 2/23/2017
Cyclacel Pharma (CYCC) Crashes as Leukemia Drug Flunks Key Late-Stage Trial 2/23/2017
AVEO Oncology (AVEO) Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review 2/23/2017
Tocagen Receives Breakthrough Therapy Designation From FDA For Toca 511 & Toca FC In Recurrent High Grade Glioma 2/23/2017
Novartis AG (NVS) Drug Zykadia Receives FDA Priority Review For First-Line Use In Patients With ALK+ Metastatic NSCLC 2/23/2017
This Drug Could Rattle Biogen (BIIB) and Be the Next Billion-Dollar Blockbuster for Celgene (CELG) 2/23/2017
Massachusetts' Agenus (AGEN) Quietly Discloses Failure of Cancer Vaccine Trial 2/22/2017
Committee Recommends Discontinuation of Argos (ARGS)' Phase III Renal Cell Carcinoma Study 2/22/2017
VBI Vaccines Receives Positive Response From Health Canada’s Initial Evaluation Of The Proposed Sci-B-Vac Phase III Clinical Program 2/22/2017
Why ImmunoGen (IMGN) Investors are Waiting on Bated Breath to Move "FORWARD" 2/22/2017
SAGE Therapeutics (SAGE) Takes Investors On A Wild Ride As CEO Talks Up Brain Drugs 2/22/2017
Trevena (TRVN)'s Painkiller Oliceridine Succeeds in Two Phase III Studies 2/21/2017
Boston Biomedical Initiates Canstem111p: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin In Patients With Metastatic Pancreatic Cancer 2/21/2017
GenSight Biologics Completes Enrollment Of REVERSE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy 2/21/2017
3 Biotechs With the Biggest and Most Promising Pipelines 2/20/2017
AstraZeneca PLC (AZN) Investors Pumped as Breast Cancer Drug Sails Through Phase III Trial 2/20/2017
After Merck & Co. (MRK) & Eli Lilly (LLY) Alzheimer’s Failures, A Look at 7 Companies Still on the Hunt 2/20/2017
Janssen Biotech (JNJ) Release: New Data Shows STELARA (ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Adult Patients With Moderately To Severely Active Crohn's Disease 2/17/2017
Janssen-Cilag International NV (JNJ) Presents Newly-Published Data On The Use Of ZYTIGA (Abiraterone Acetate) Plus Prednisone In The Real-World, Outside The Clinical Trial Setting1 2/17/2017
Takeda (TKPYY) And TiGenix Report New Data Highlighting Maintenance Of Long-Term Remission Of Complex Perianal Fistulas In Crohn’s Disease Patients With Cx601 2/17/2017
Aimmune (AIMT) Provides Update On Ongoing AR101 Phase 3 Program For Peanut Allergy Based On FDA Feedback 2/17/2017
Myriad Genetics (MYGN)’s Bracanalysis CDx Test Successfully Identified Metastatic Breast Cancer Patients With Improved Outcomes From AstraZeneca PLC (AZN)'s PARP Inhibitor, Olaparib 2/17/2017
ArQule (ARQL), Daiichi Sankyo's Liver Cancer Drug Comes Up Short in Another Phase III Study 2/17/2017
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug 2/17/2017
Pfizer (PFE) Release: New Data In Crohn’s Disease Patients Shows Similar Efficacy And Safety Profiles For INFLECTRA And REMICADE 2/17/2017
Celltrion Healthcare (068270.KQ) Releases Positive Results From Pivotal Study In Crohn’s Disease 2/17/2017
AstraZeneca PLC (AZN) Release: Updated Durvalumab Monotherapy Data Confirm Results In Urothelial Bladder Cancer 2/17/2017
Immune Pharma Announces The Launch Of REMAIN, An International Overall Survival Study With Ceplene And Low Dose Proleukin In Remission Maintenance In Acute Myeloid Leukemia 2/17/2017
Denovo Biopharma Plans To Initiate A Global Phase III Trial Of DLBCL Drug 2/17/2017
Celgene (CELG) Announces Positive Results From Phase III SUNBEAM Trial Of Oral Ozanimod In Patients With Relapsing Multiple Sclerosis 2/17/2017
Bay Area Biotech Ardelyx (ARDX) Rejoices as Lead Drug Hits Phase III Goals 2/16/2017
Pfizer (PFE) Announces Top-Line Results From The Oral Strategy Trial Of XELJANZ (Tofacitinib Citrate) Compared To Humira (Adalimumab) 2/16/2017
Amgen (AMGN)’s Repatha CVOT Results Are Potential Game-Changer For Lipid-Lowering Treatment 2/16/2017
Eli Lilly (LLY) Release: Additional Results From Pivotal RA-BEAM Study Published In The New England Journal of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo 2/16/2017
Denovo Biopharma Plans To Launch A Global Phase III Trial Of DB102 (Enzastaurin) In Diffuse Large B-Cell Lymphoma 2/16/2017
City of Hope To Manufacture NurOwn For BrainStorm Cell's Phase III ALS Clinical Trial 2/16/2017
TRACON Pharma (TCON) Announces First Patient Dosed In Phase III TAPPAS Trial Of TRC105 In Angiosarcoma 2/16/2017
Merck & Co. (MRK)'s Alzheimer's Failure Has All Eyes and Hopes Turning to Biogen (BIIB) 2/16/2017
Roche (RHHBY) Faces Off With Itself for $9 Billion Breast Cancer Drug Business 2/15/2017
2 Biotechs Taking on the $20 Billion Alzheimer's Market Full Force 2/15/2017
Gilead (GILD) Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya For Treatment Of HIV-1 In Treatment-Naïve Adults 2/15/2017
Theratechnologies (TH.TO) Announces New Data From The Pivotal Phase III Trial Of HIV Monoclonal Antibody And Long-Acting Investigational Antiretroviral Ibalizumab 2/15/2017
Merck & Co. (MRK)’s Doravirine, An Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) For The Treatment Of HIV-1 Infection, Met Primary Efficacy Endpoint In Pivotal Phase III Trial 2/15/2017
First Patient Enrolled In NovoCure’s Phase III Pivotal LUNAR Trial Testing Tumor Treating Fields For The Treatment Of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy 2/15/2017
Amgen (AMGN)’s Repatha CVOT Results Are Potential Game-Changer For Lipid-Lowering Treatment 2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Gilead (GILD) Looks Over Its Shoulder as GlaxoSmithKline (GSK) Gains Ground With New HIV Phase III Trial Data 2/14/2017
SAVSU Provides Performance Update On Evo Cold Chain 2.0 System In ImmunoCellular Therapeutics (IMUC) Phase lll Glioblastoma Cell Therapy Clinical Trial 2/14/2017
Armetheon Announces EMA's Support For 1000 Patient Single Phase lll Study Prior To MAA Filing For Its Novel Oral Anticoagulant Tecarfarin 2/14/2017
Ohr Pharma (OHRP) Pauses Enrollment of Phase III Trial of Its Lead Drug 2/14/2017
Janssen Announces Two-Drug Combination Of Dolutegravir And Rilpivirine Demonstrates Efficacy In Maintaining Viral Suppression In Phase III Clinical Studies 2/14/2017
Axsome (AXSM) Receives FDA Fast Track Designation For AXS-05 For Treatment Resistant Depression 2/14/2017
Global Blood Therapeutics (GBT) Announces Publication Of Paper Describing Discovery Of GBT440 In American Chemical Society Medicinal Chemistry Letters 2/14/2017
Bay Area's Zosano (ZSAN) Surges After Migraine Patch Hits Goals in Late-Stage Study 2/13/2017
Acacia Pharma Announces Positive Results From Its Fourth And Final Pivotal Trial Of BAREMSIS For The Rescue Treatment Of PONV 2/13/2017
eMD Release: Cladribine Tablets Significantly Reduced Brain Atrophy In Patients With Multiple Sclerosis 2/13/2017
Resverlogix (RVX.TO) Highlights Unique Properties Of Apabetalone In Both A Rare Muscular Dystrophy (FSHD) And Neurodegenerative Eye Disease 2/13/2017
Zogenix (ZGNX) Announces Initiation Of Clinical Efficacy Portion Of Study 1504 For ZX008 In Dravet Syndrome 2/13/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In BEKINDA Phase III Study For Acute Gastroenteritis 2/13/2017
Why Intercept Pharma (ICPT) Stock Jumped Nearly 10% On Friday After Providing Phase III Update 2/13/2017
Acorda (ACOR) Rockets After Parkinson's Drug Hits Late-Stage Goals 2/10/2017
AVEO Oncology (AVEO) Announces Clinical And Regulatory Updates For Tivozanib 2/10/2017
Seattle Genetics (SGEN) Reports Fourth Quarter And Year 2016 Financial Results 2/10/2017
Neurocrine Biosciences (NBIX) Nabs North American Rights to Bial's ONGENTYS 2/10/2017
Armetheon Reaches Agreement With FDA To Conduct A 1000 Patient Single Phase 3 Study Prior To NDA Filing For Its Novel Oral Anticoagulant Tecarfarin 2/9/2017
Promising Phase III Data for Bayer (BAY)’s Xarelto Leads to Early Halt of Study 2/9/2017
New FDA Report Cites 22 Drugs That Passed Phase II But Crashed and Burned in Phase III 2/8/2017
H. Lundbeck A/S (LUN.CO) Throws in the Towel on Alzheimer's Pill, Giving Leeway to Rival Axovant (AXON) 2/8/2017
Onxeo: Information On ReLive Trial Design And Role Of Its Data Safety And Monitoring Board 2/8/2017
Can-Fite BioPharma (CFBI) Gears Up For ACRobat, Its Phase III Trial Of Piclidenoson In Rheumatoid Arthritis 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Mithra Pharmaceuticals Completes Recruitment For European Phase III Estelle Study 2/7/2017
Biofrontera AG Reports Positive Phase III Results For Ameluz In Combination With Daylight-PDT 2/7/2017
VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac Phase III Clinical Study 2/7/2017
Taxus Cardium (CRXM) Release: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease 2/7/2017
Why Struggling Alkermes (ALKS) Could Make a Comeback in 2017 2/7/2017
FDA Lifts Clinical Hold on NW Bio (NWBO)'s Phase III Cancer Vaccine Trial 2/7/2017
Synergy Pharma (SGYP) Release: Pivotal Phase III Data Results For TRULANCE (Plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology 2/7/2017
AstraZeneca PLC (AZN) Quietly Kills Some Programs 2/6/2017
These 5 Biotechs Are Battling Over the $10 Billion Hemophilia Market 2/6/2017
Kiadis Pharma Issues Clinical And Regulatory Progress Update On ATIR101 And ATIR201 2/6/2017
5 Daring Biopharmas Mixing Drugs With Marijuana 2/6/2017
Amgen (AMGN)'s Cholesterol-Lowering Drug Repatha Wows in Huge Heart Study 2/3/2017
Sobi - Long-Term Safety And Efficacy Data Of Extended Half-Life Therapy Alprolix In Children With Haemophilia B Published In The Lancet Haematology 2/2/2017
Nabriva Confirms No Sample Size Adjustment Required For LEAP 1 Phase III Trial Of Lefamulin In Community Acquired Bacterial Pneumonia 2/2/2017
Bioverativ (BIVVV) Release: Long-Term Safety And Efficacy Data Of Extended Half-Life Therapy ALPROLIX In Children With Hemophilia B Published In The Lancet Hematology 2/2/2017
Eli Lilly (LLY) Washes Its Hands of Another Phase 3 Study After the Failure of Solanezumab 2/2/2017
AstraZeneca PLC (AZN) Investors Nervous as Its Recovery Hinges on the Success of New Meds and Key Drug Data 2/2/2017
Radius Health (RDUS) Release: Mayo Clinic Proceedings Publishes Positive Results From The Activextend Clinical Trial Of Abaloparatide-SC In Postmenopausal Women With Osteoporosis 2/1/2017
Collegium (COLL) Announces Positive Topline Results Of Human Abuse Potential Clinical Trial Evaluating The Oral Abuse Of Xtampza ER 2/1/2017



//-->